BioCentury | Jan 13, 2014
Company News

Cernostics, Academic Medical Center deal

...Academic Medical Center (AMC) will provide Cernostics with access to a Barrett's esophagus patient registry, which...
...development of esophageal cancer in patients with Barrett's esophagus. Cernostics declined to disclose deal terms. Cernostics Inc....
BioCentury | Dec 9, 2013
Financial News

Cernostics completes venture financing

Cernostics Inc. , Pittsburgh, Pa. Business: Diagnostic Date completed: 12/3/13 Type: Venture financing Raised: $1.4 million Investors: Novitas Capital; Geisinger Health System; Pittsburgh Life Sciences Greenhouse WIR Staff Diagnostic...
BioCentury | Jul 21, 2008
Company News

Cellumen diagnostic, pharmacogenetics news

...Cellumen spun out its personalized medicine unit into Cernostics Pathology Inc. The spinout will provide digital...
...and diagnostics for personalized medicine. Cellumen CEO D. Lansing Taylor will serve as chairman of Cernostics...
...better address market demands and maintain its focus on early drug discovery and toxicity testing. Cernostics’...
Items per page:
1 - 3 of 3
BioCentury | Jan 13, 2014
Company News

Cernostics, Academic Medical Center deal

...Academic Medical Center (AMC) will provide Cernostics with access to a Barrett's esophagus patient registry, which...
...development of esophageal cancer in patients with Barrett's esophagus. Cernostics declined to disclose deal terms. Cernostics Inc....
BioCentury | Dec 9, 2013
Financial News

Cernostics completes venture financing

Cernostics Inc. , Pittsburgh, Pa. Business: Diagnostic Date completed: 12/3/13 Type: Venture financing Raised: $1.4 million Investors: Novitas Capital; Geisinger Health System; Pittsburgh Life Sciences Greenhouse WIR Staff Diagnostic...
BioCentury | Jul 21, 2008
Company News

Cellumen diagnostic, pharmacogenetics news

...Cellumen spun out its personalized medicine unit into Cernostics Pathology Inc. The spinout will provide digital...
...and diagnostics for personalized medicine. Cellumen CEO D. Lansing Taylor will serve as chairman of Cernostics...
...better address market demands and maintain its focus on early drug discovery and toxicity testing. Cernostics’...
Items per page:
1 - 3 of 3